{"DataElement":{"publicId":"2635476","version":"1","preferredName":"Acute Graft Versus Host Disease Skin Involvement Maximum Grade","preferredDefinition":"the maximum grade or stage acute graft versus host disease, a syndrome of immologically mediated tissue damage occurring following allogeneic transplant,  affecting the skin, the organ and the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all of the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands, and mammary glands, with onset is usually within one hundred days of transplantation or immunologic manipulation.","longName":"AGVHD_SK_INVLT_M_GD","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2635431","version":"1","preferredName":"Acute Graft Versus Host Disease Skin Involvement","preferredDefinition":"information related to the acute graft versus host disease, a syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract with onset is usually within one hundred days of transplantation or immunologic manipulation, involving the skin, the organ and the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all of the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands, and mammary glands.","longName":"AGVHD_SKIN_INVLT","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2512823","version":"1","preferredName":"Acute Graft Versus Host Disease","preferredDefinition":"A graft versus host disease with symptoms appearing within the first 100 days post-transplant, but with short duration.","longName":"C4980","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898438-B0B8-35BB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2593684","version":"1","preferredName":"Skin Involvement","preferredDefinition":"1. An organ and the enveloping membrane of the body; includes, in addition to the epidermis and dermis, all of the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands, and mammary glands. Subdivisions of the skin surround various body parts; as a whole, the skin constitutes the external surface of the body. 2. The rind, capsule, or covering of any body or part.:To have a connection by participation or association or use; sharing in an activity or process.","longName":"C12470:C25548","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin","conceptCode":"C12470","definition":"An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C6403D-C752-4B7A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-05","modifiedBy":"ONEDATA","dateModified":"2007-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F7EF2B9-0B6C-5EAF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2635468","version":"1","preferredName":"Acute Graft Versus Host Disease Skin Maximum Grade","preferredDefinition":"The largest possible scale of intensity of acute graft versus host disease involving the skin.","longName":"AGVHD_SKIN_MAX_GD","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"9","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage I","valueDescription":"Maculopapular rash <25% of body surface","ValueMeaning":{"publicId":"2635478","version":"1","preferredName":"Maculopapular rash <25% of body surface","longName":"2635478","preferredDefinition":"Maculopapular rash <25% of body surface","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F817735-F5A4-08A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F817D7C-57BE-0762-E044-0003BA3F9857","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"ONEDATA","dateModified":"2007-05-02","deletedIndicator":"No"},{"value":"Stage 0","valueDescription":"No Rash","ValueMeaning":{"publicId":"2635477","version":"1","preferredName":"No Rash","longName":"2635477","preferredDefinition":"No Rash","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F7FAA5E-EFCE-6B09-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F817D7C-57AC-0762-E044-0003BA3F9857","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"ONEDATA","dateModified":"2007-05-02","deletedIndicator":"No"},{"value":"Stage II","valueDescription":"Maculopapular rash 25%-50% of body surface","ValueMeaning":{"publicId":"2635479","version":"1","preferredName":"Maculopapular rash 25%-50% of body surface","longName":"2635479","preferredDefinition":"Maculopapular rash 25%-50% of body surface","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F81790A-405D-08B5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F817D7C-57D0-0762-E044-0003BA3F9857","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"ONEDATA","dateModified":"2007-05-02","deletedIndicator":"No"},{"value":"Stage III","valueDescription":"Maculopapular rash >50% body surface area or generalized erythroderma","ValueMeaning":{"publicId":"2635480","version":"1","preferredName":"Maculopapular rash >50% body surface area or generalized erythroderma","longName":"2635480","preferredDefinition":"Maculopapular rash >50% body surface area or generalized erythroderma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F8170E5-692F-0620-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F817D7C-57E2-0762-E044-0003BA3F9857","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"ONEDATA","dateModified":"2007-05-02","deletedIndicator":"No"},{"value":"Stage IV","valueDescription":"Generalized erythroderma with bullous formation and desquamation","ValueMeaning":{"publicId":"2635481","version":"1","preferredName":"Generalized erythroderma with bullous formation and desquamation","longName":"2635481","preferredDefinition":"Generalized erythroderma with bullous formation and desquamation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F817735-F5B4-08A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2F817D7C-57F4-0762-E044-0003BA3F9857","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"ONEDATA","dateModified":"2007-05-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2635467","version":"1","preferredName":"Maximum Grade","preferredDefinition":"the largest possible quantity or degree.:A position on a scale of intensity or amount or quality.","longName":"C25564:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maximum","conceptCode":"C25564","definition":"The largest possible quantity or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F7FEB1F-64AC-7116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"ONEDATA","dateModified":"2007-05-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F7FEB1F-64BD-7116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"CAMPBELB","dateModified":"2016-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"},{"name":"AcuGvhdSkn2St","type":"COG Form Element","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"Maximum Stage of GVHD of the","type":"Preferred Question Text","description":"Maximum Stage of GVHD of the Skin","url":null,"context":"NHLBI"},{"name":"CRF Text","type":"Alternate Question Text","description":"Skin Abnormality","url":null,"context":"NHLBI"},{"name":"CRF TEXT","type":"Alternate Question Text","description":"Stage of acute GVHD of the Skin:","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Peak GVHD stage:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"What is patients maximum stage of GvHD?","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Highest stage for organ:","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Highest stage for skin:","url":null,"context":"COG"},{"name":"COG CRF TEXT 5","type":"Alternate Question Text","description":"What is the maximum grade?","url":null,"context":"COG"}],"origin":"Transplant CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F8164F5-DB78-0674-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-05-02","modifiedBy":"KUMMEROA","dateModified":"2021-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}